Tag:
Contingent value right
Latest Headlines
Latest Headlines
Biotie snares Newron CNS pipeline in $63M share/CVR deal
Finland's Biotie Therapies has struck a deal to acquire Newron Pharmaceuticals ( $NWRN ) for up to $63 million worth of shares. The tie-up--which includes a significant amount tied up in CVRs--creates
CVRs: The next big thing in biotech deals?
Yesterday we reported that Sanofi-Aventis and Genzyme continuing negotiations. But this financial representatives for both companies were hashing out the specifics of a contingent value right, or
